Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED50 of remimazolam with nalbuphine for painless gastroscopy and gender effect
ChiCTR2300067878Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam and nalbuphine (3 arms), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoints: Median effective dose of remimazolam, Remimazolam ED50 in female patients and 1 more. Started Feb 2023; status: recruiting.
02
Drugs
remimazolamnalbuphine
Beyond the preview
Go deeper on ChiCTR2300067878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067878.